Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
216 hedge funds and large institutions have $2.12B invested in Sage Therapeutics in 2021 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 78 increasing their positions, 74 reducing their positions, and 33 closing their positions.
64% more call options, than puts
Call options by funds: $53.2M | Put options by funds: $32.4M
1.75% more ownership
Funds ownership: 83.45% → 85.19% (+1.7%)
5% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 74
3% less capital invested
Capital invested by funds: $2.17B → $2.12B (-$55.3M)
4% less funds holding
Funds holding: 225 → 216 (-9)
18% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 33
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$39.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$17.9M |
| 3 |
JP Morgan Chase
New York
|
+$16.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$14.9M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$9.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17.6M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$11.9M |
| 3 |
D.E. Shaw & Co
New York
|
-$11M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.6M |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$10.2M |
SAGE Hedge Fund Activity: Q4 2021 in Review
216 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2021, worth a combined $2.12B — down 2.5% from $2.17B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of SAGE and 27 opened new positions — a net loss of 6 holders — while 74 trimmed existing stakes and 78 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $39.4M. The largest seller was Point72 Asset Management, cutting an estimated $17.6M.
- 216 institutional investors held Sage Therapeutics (SAGE) as of Q4 2021, down from 225 in Q3 2021.
- Funds reported $2.12B of Sage Therapeutics stock for Q4 2021, down 2.5% quarter-over-quarter.
- 27 funds opened new Sage Therapeutics positions in Q4 2021 and 33 closed out, a net change of -6 holders.
- The largest Sage Therapeutics buyer in Q4 2021 was EcoR1 Capital, an estimated $39.4M added.
- The largest Sage Therapeutics seller in Q4 2021 was Point72 Asset Management, an estimated $17.6M sold.
Based on aggregated 13F filings for Q4 2021.